Antidepressant drugs: Does it matter if they inhibit the reuptake of noradrenaline or serotonin?

Acta Psychiatrica Scandinavica, Supplement

Volumn 101, Issue 402, 2000, Pages 12-17

  Eriksson, Elias ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Antidepressants; Behaviour; Catecholamines; Depression; Noradrenaline; R eboxetine; Serotonin

Indexed keywords

ANTIDEPRESSANT AGENT; BRAIN MONOAMINE; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; ADRENERGIC RECEPTOR AFFECTING AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

DEPRESSION; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; HUMAN; REVIEW; SEROTONINERGIC SYSTEM; METABOLISM;

ADRENERGIC UPTAKE INHIBITORS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSION; HUMANS; NOREPINEPHRINE; SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 0034039660     PISSN: 00651591     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. 1. DELAY J, LAINÉ B, BUISSON JF. Note concernant l'action de l'isonicotinylhydrazide dans le traitement des etats dépressifs. Ann Méd Psychol 1952;110:689-692.
2. 2. KUHN R. The treatment of depressive states with G22355 (imipramine hydrochloride). Am J Psychiatry 1958;115: 459-464.
3. 3. ZELLER EA, BARSKY J. In vivo inhibition of liver and brain monoamine oxidase by 1-isonicotinyl-2-isopropyl hydrazine. Proc Soc Exp Biol Med 1995;81:459-461.
4. 4. GLOWINSKI J, ALEXROD J. Inhibition of uptake of tritiated noradrenaline in the intact rat brain by imipramine and structurally related compounds. Nature 1964;204:1318-1319.
5. 5. CARLSSON A, CORRODI H, FUXE K, HÖKFELT T. Effect of antidepressant drugs on the depletion of intraneuronal brain 5-hydroxytryptamine stores caused by 4-methyl-alpha-ethyl-meta-tyramine. Eur J Pharmacol 1969;5:357-366.
6. 6. GOODWIN FK, BUNNEY WE JR. Depressions following reserpine: a re-evaluation. Semin Psychiatry 1971;3:435-448.
7. 7. SCHILDKRAUT JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965;122:509-552.
8. 8. VAN PRAAG HM. Antidepressants, catecholamines and 5-hydroxyindoles. Trends towards a more specific research in the field of antidepressants. Psychiatr Neurol Neurochir 1967;70:219-233.
9. 9. COPPEN AJ. Biochemical aspects of depression. Int Psychiatr Clin 1969;6:53-81.
10. 10. SHOPSIN B, GERSHON S, GOLDSTEIN M, FRIEDMAN E, WILK S. Use of synthesis inhibitors in defining a role for biogenic amines during imipramine treatment in depressed patients. Psychopharmacol Commun 1975;1:239-249.
11. 11. SHOPSIN B, FRIEDMAN E, GERSHON S. Parachlorophenylalanine reversal of tranylcypromine effects in depressed patients. Arch Gen Psychiatry 1976;33:811-819.
12. 12. JENSEN K, FRUENSGAARD K, AHLFORS UG et al. Tryptophan/ imipramine in depression (Letter). Lancet 1975;2:920.
13. 13. WALINDER J, SKOTT A, NAGY A, CARLSSON A, ROOS BE. Potentiation of antidepressant action of clomipramine by tryptophan. Lancet 1975;1:984.
14. 14. VAN PRAAG HM. Serotonin percursors in the treatment of depression. Adv Biochem Psychopharmacol 1982;34:259-286.
15. 15. CARLSSON A. Some current problems related to the mode of action of antidepressant drugs. Acta Psychiatr Scand 1981; 290:63-66.
16. 16. FULLER RW. Serotonin uptake inhibitors: uses in clinical therapy and in laboratory research. Prog Drug Res 1995; 45:167-204.
17. 17. BOUCHARD JM, DELAUNAY J, DELISLE JP et al. Citalopram versus maprotiline: a controlled, clinical multicentre trial in depressed patients. Acta Psychiatr Scand 1987;76:583-593.
18. 18. NYSTRÖM C, HÄLLSTRÖM T. Comparison between a serotonin and a noradrenaline reuptake blocker in the treatment of depressed outpatients. A cross-over study. Acta Psychiatr Scand 1987;75:377-382.
19. 19. DUBINI A, BOSC M, POLIN V. Do noradrenaline and serotonin differentially affect social motivation and behaviour? Eur Neuropsychopharmacol 1997;7:S49-S55.
20. 20. ERIKSSON E, HUMBLE M. Serotonin in psychiatric pathophysiology. A review of data from experimental and clinical research. In: POHL R, GERSHON S, eds. The biological basis of psychiatric treatment. Prog Basic Clin Pharmacol. Basel: Karger, 1990;66-119.
21. 21. MCRAE-DEGUEURCE A, BEROD A, MERMET A et al. Alterations in tyrosine hydroxylase activity elicited by raphe nuclei lesions in the rat locus coeruleus: evidence for the involvement of serotonin afferents. Brain Res 1982;11:285-301.
22. 22. SHIEKHATTER R, ASTON-JONES G. Sensory responsiveness of brain noradrenergic neurones is modulated by endogenous brain serotonin. Brain Res 1993;623:72-76.
23. 23. SVENSSON TH. Brain noradrenaline and the mechanisms of action of antidepressant drugs. Acta Psychiatr Scand 2000; 101(Suppl. 402):18-27.
24. 24. WALDINGER MD, OLIVIER B. Selective serotonin reuptake inhibitor-induced sexual dysfunction: clinical and research considerations. Int Clin Psychopharmacol 1998;13:S27-S33.
25. 25. THORÉN P, ÅSBERG M, CRONHOLM B, JÖRNESTEDT L, TRÄSKMAN L. Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial. Arch Gen Psychiatry 1980;37:1281-1285.
26. 26. DEN BOER JA, WESTENBERG HG. Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 1988;3:59-74.
27. 27. MODIGH K, WESTBERG P, ERIKSSON E. Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. J Clin Psychopharmacol 1992;12: 251-261.
28. 28. ERIKSSON E, HEDBERG MA, ANDERSCH B, SUNDBLAD C. The serotonin reuptake inhibitor paroxetine is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology 1995;12:167-176.
29. 29. HENINGER GR, DELGADO PL, CHARNEY DS. The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. Pharmacopsychiatry 1996;29:2-11.
30. 30. FOOTE SL, BLOOM FE, ASTON-JONES G. Nucleus locus coeruleus: new evidence of anatomical and physiological specificity. Physiol Rev 1983;63:844-914.
31. 31. JACOBS BL, ABERCROMBIE ED, FORNAL CA, LEVINE ES, MORILAK DA, STAFFORD IL. Single-unit and physiological analyses of brain norepinephrine function in behaving animals. Prog Brain Res 1991;88:159-165.
32. 32. AL-ZAHRANI SS, AL-RUWAITEA AS, HO MY, BRADSHAW CM, SZABADI E. Effect of destruction of noradrenergic neurones with DSP4 on performance on a free-operant timing schedule. Psychopharmacology 1998;136:235-242.
33. 33. ROBBINS TW, GRANON S, MUIR JL et al. Neural systems underlying arousal and attention. Implications for drug abuse. Ann NY Acad Sci 1998;846:222-237.
34. 34. VAN PRAAG HM, KAHN R, ASNIS GM, LEMUS CZ, BROWN SL. Therapeutic indications for serotonin-potentiating compounds: a hypothesis. Biol Psychiatry 1987;22:205-212.
35. 35. ÅBERG A. Controlled cross-over study of a 5-HT uptake inhibiting and an NA uptake inhibiting antidepressant. Acta Psychiatr Scand 1981;290:244-255.
36. 36. VESTERGAARD P, GRAM LF, KRAGH-SORENSEN P, BECH P, REISBY N, BOLWIG TG. Therapeutic potentials of recently introduced antidepressants. Psychopharmacol Ser 1993;10: 190-198.
37. 37. ROOSE SP, GLASSMAN AH, ATTIA E, WOODRING S. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry 1994;151:1735-1739.
38. 38. CLERC GE, RUIMY P, VERDEAU-PALLES J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 1994;9:139-143.
39. 39. PUFCH A, MONTGOMERY SA, PROST JF, SOLLES A, BRILEY M. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol 1997;12: 99-108.
40. 40. NELSON JC, MAZUE CM, BOWERS MB JR, JATLOW PI. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 1991;48:303-307.
41. 41. DAM J, RYDE L, SVEJSO J, LAUGE N, LAURITSEN B, BECH P. Morning fluoxetine plus evening mainserin versus morning fluoxetine plus evening placebo in the acute treatment of major depression. Pharmacopsychiatry 1998;31:48-54.
42. 42. MONTGOMERY SA. Reboxetine: additional benefits to the depressed patient. Psychopharmacology 1997;11:S9-S15.
43. 43. BURROWS GD, MAGUIRE KP, NORMAN TR. Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review. J Clin Psychiatry 1998;59:4-7.